Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs PHEBURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Adjunct therapy for nitrogen removal in patients with urea cycle disorders (UCDs) involving deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase,Off-label: Management of hyperammonemia in other conditions
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged (up to 4-6 hours), necessitating dose adjustment.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily hepatic and renal; hydrolyzed by esterases to phenylacetate; phenylacetate then conjugated with glutamine via acyl-Co A synthetase and acyl-Co A:glutamine N-acyltransferase to form phenylacetylglutamine.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Primarily renal excretion. Approximately 50-80% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Low protein binding; 0–11% bound, primarily to albumin.
Approximately 10-20% bound to plasma proteins, primarily albumin. Binding is low and not clinically significant.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid. Not extensively distributed into tissues.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Oral bioavailability is approximately 80-100% after administration of the sodium phenylbutyrate prodrug. PHEBURANE itself is a prodrug; bioavailability refers to conversion to phenylacetate and then to phenylacetylglutamine.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Contraindicated in patients with GFR < 50 m L/min/1.73 m² due to risk of hyperammonemia.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
No specific adjustment recommended for Child-Pugh A or B. Use with caution in severe hepatic impairment (Child-Pugh C) due to limited data.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Neonates and children: 4.5 to 5.9 grams/m²/day orally in 2 to 4 divided doses. Doses up to 12.5 grams/day have been used.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No specific adjustments recommended; use with caution due to age-related renal decline. Monitor renal function and ammonia levels.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
None
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
May cause fluid retention and electrolyte abnormalities (e.g., hypernatremia, hypokalemia) due to sodium content,Pancreatitis has been reported,Neurotoxicity with high plasma phenylacetate levels (e.g., somnolence, confusion, seizures),May impair platelet function; caution in bleeding disorders or surgery,Monitor ammonia levels, serum electrolytes, liver function, and complete blood counts regularly
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Hypersensitivity to sodium phenylbutyrate or any component of the formulation,Patients in whom adequate nitrogen removal cannot be achieved or who are not suitable for alternative therapy (e.g., hemodialysis)
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Avoid high-protein foods as they increase ammonia production. Take with meals to improve tolerability. No known significant food-drug interactions.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Pheburance (sodium phenylbutyrate) has not been studied in pregnant women. In animal studies, phenylbutyrate caused fetal harm at doses equivalent to human therapeutic doses. First trimester: Potential for teratogenicity based on animal data. Second and third trimesters: May cause fetal growth restriction and neurotoxicity due to ammonia-lowering effects. Use only if benefit outweighs risk.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
It is unknown if sodium phenylbutyrate or its metabolites are excreted in human milk. The M/P ratio has not been established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Pregnancy may alter pharmacokinetics of sodium phenylbutyrate due to increased plasma volume, renal clearance, and hepatic metabolism. Although specific dose adjustment recommendations are lacking, consider monitoring ammonia levels closely and titrating dose to maintain therapeutic ammonia control. Dose may need to be increased in late pregnancy and postpartum. Start at the lowest effective dose.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
PHEBURANE (sodium phenylbutyrate) is used as adjunctive therapy for urea cycle disorders. Monitor plasma ammonia, arginine, and glutamine levels. Avoid in patients with severe hepatic impairment. Discontinue if hyperammonemic encephalopathy occurs.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
Take with food or milk to reduce gastrointestinal irritation.,Do not crush or chew tablets; swallow whole.,Report any signs of hyperammonemia (e.g., lethargy, vomiting, confusion) immediately.,Maintain a low-protein diet as prescribed.,Store at room temperature away from moisture and heat.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs PHEBURANE, answered by our medical review team.
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. PHEBURANE is a Ammonia Detoxicant that works by Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and PHEBURANE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. The standard adult dose of PHEBURANE is: Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and PHEBURANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. PHEBURANE is classified as Category C. Pheburance (sodium phenylbutyrate) has not been studied in pregnant women. In animal studies, phenylbutyrate caused fetal harm at doses equivalent to human therapeutic doses. First. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.